ok so i saw in the investor presentation a $100m ARR target value by cy2021... it could go something like this... assume $13.3m pa organic growth between now and 2021 (low considering history) with an annual acquisition netting a further $10m pa puts them at $100m ARR and with an 10x multiplier that's $1bn value. hoping the focus to improve operating cash flow will help the multiplier more. Assume dilution of 50m shares per acquisition taking the ~660m to 810m and a $1bn valuation makes the shares worth $1.23. I have no idea on the acquisition strategy, I'd actually assume higher balance of organic ARR growth so pls DYOR.
- Forums
- ASX - By Stock
- Ann: Successful completion of capital raise
ok so i saw in the investor presentation a $100m ARR target...
Featured News
Add LVT (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Andy Udell, CCO
Andy Udell
CCO
SPONSORED BY The Market Online